Business Context and Reporting Period
X4 Pharmaceuticals, Inc. (XFOR) filed this Form 8-K on March 3, 2022, to disclose the entry into a Material Definitive Agreement. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Boston, Massachusetts.
Key Financial Metrics and Transaction Details
This filing reports a private placement transaction rather than periodic financial results. Key metrics include:
- Transaction Type: Private placement of common stock and pre-funded warrants.
- Investor: BCLS II Investco, LP, an affiliate of Bain Capital Life Sciences.
- Securities Issued: 900,000 shares of Common Stock and pre-funded warrants to purchase 766,666 shares.
- Pricing: Common Stock at $1.80 per share; Pre-Funded Warrants at $1.79 per warrant.
- Expected Proceeds: Approximately $3.0 million in aggregate gross proceeds.
- Use of Proceeds: Clinical development pipeline, business development, working capital, and general corporate purposes.
Material Changes and Agreements
The Company entered into two primary agreements on March 3, 2022:
- Securities Purchase Agreement: Establishes the terms of the private placement. Pre-funded warrants are exercisable immediately and do not expire, subject to a 9.99% beneficial ownership limitation (adjustable up to 19.99% with notice).
- Registration Rights Agreement: Requires the Company to file a registration statement for the resale of securities by April 30, 2022. Failure to file or maintain effectiveness may trigger liquidated damages of 1% of the investment per 30-day period.
Outlook, Risks, and Contingencies
Covenant Extension: The proceeds from this private placement qualify as third-party funding under the Company's loan agreement with Hercules Capital Inc. Consequently, the initial test date for the minimum cash covenant is expected to be extended from April 1, 2022, to September 1, 2022.
Risks and Contingencies:
- The transaction is subject to customary closing conditions, with an expected closing date of March 7, 2022.
- Forward-looking statements regarding proceeds and covenant satisfaction are subject to risks, including the inability to satisfy closing conditions.
- The securities are unregistered and sold in reliance on Section 4(a)(2) of the Securities Act.
Investor Verification Checklist
- Confirm the actual closing of the private placement on or about March 7, 2022.
- Verify the filing of the registration statement for resale by the April 30, 2022 deadline.
- Monitor the Company's cash position to ensure compliance with the extended minimum cash covenant starting September 1, 2022.
- Review the definitive Securities Purchase Agreement (Exhibit 10.1) for specific closing conditions and representations.